JP2022531696A5 - - Google Patents
Info
- Publication number
- JP2022531696A5 JP2022531696A5 JP2021565932A JP2021565932A JP2022531696A5 JP 2022531696 A5 JP2022531696 A5 JP 2022531696A5 JP 2021565932 A JP2021565932 A JP 2021565932A JP 2021565932 A JP2021565932 A JP 2021565932A JP 2022531696 A5 JP2022531696 A5 JP 2022531696A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- item
- patient
- amount
- symptoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024187589A JP2025013963A (ja) | 2019-05-09 | 2024-10-24 | 特定のｖｍａｔ２阻害剤を投与するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962845599P | 2019-05-09 | 2019-05-09 | |
| US62/845,599 | 2019-05-09 | ||
| PCT/US2020/032188 WO2020227672A1 (en) | 2019-05-09 | 2020-05-08 | Methods for the administration of certain vmat2 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024187589A Division JP2025013963A (ja) | 2019-05-09 | 2024-10-24 | 特定のｖｍａｔ２阻害剤を投与するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022531696A JP2022531696A (ja) | 2022-07-08 |
| JP2022531696A5 true JP2022531696A5 (enExample) | 2023-05-15 |
Family
ID=70919120
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021565932A Pending JP2022531696A (ja) | 2019-05-09 | 2020-05-08 | 特定のｖｍａｔ２阻害剤を投与するための方法 |
| JP2024187589A Pending JP2025013963A (ja) | 2019-05-09 | 2024-10-24 | 特定のｖｍａｔ２阻害剤を投与するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024187589A Pending JP2025013963A (ja) | 2019-05-09 | 2024-10-24 | 特定のｖｍａｔ２阻害剤を投与するための方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20200397779A1 (enExample) |
| EP (1) | EP3965764A1 (enExample) |
| JP (2) | JP2022531696A (enExample) |
| KR (1) | KR20220007105A (enExample) |
| CN (1) | CN114340624A (enExample) |
| AU (2) | AU2020270145A1 (enExample) |
| BR (1) | BR112021020709A2 (enExample) |
| CA (1) | CA3136466A1 (enExample) |
| EA (1) | EA202193012A1 (enExample) |
| IL (2) | IL321020A (enExample) |
| JO (1) | JOP20210274A1 (enExample) |
| MA (1) | MA55893A (enExample) |
| MX (1) | MX2021013132A (enExample) |
| PH (1) | PH12021552745A1 (enExample) |
| SG (1) | SG11202111465RA (enExample) |
| TW (1) | TWI850377B (enExample) |
| WO (1) | WO2020227672A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230170136A (ko) | 2017-01-27 | 2023-12-18 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| CA3076000A1 (en) | 2017-09-21 | 2019-03-28 | Neurocrine Biosciences, Inc. | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| US20200230127A1 (en) | 2017-10-10 | 2020-07-23 | Neurocrine Biosciences, Inc. | Methods for the Administration of Certain VMAT2 Inhibitors |
| SG11202100303QA (en) | 2018-08-15 | 2021-02-25 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| IL309172A (en) * | 2021-06-30 | 2024-02-01 | Neurocrine Biosciences Inc | Vulbanazine for use in the additional treatment of schizophrenia |
| CA3229341A1 (en) | 2021-08-20 | 2023-02-23 | Ryan TERRY-LORENZO | Methods of screening for vmat2 inhibitors |
| CA3245030A1 (en) * | 2022-03-07 | 2023-09-14 | Neurocrine Biosciences, Inc. | VALBENAZINE, A VMAT2 INHIBITOR, AS A FREE BASE OF A TOSYLATE OR DITOSYLATE SALT, INTENDED FOR USE IN THE TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE |
| TW202521119A (zh) * | 2023-08-17 | 2025-06-01 | 美商紐羅克里生物科學有限公司 | 用於投與特定vmat2抑制劑之方法 |
| WO2025038959A1 (en) * | 2023-08-17 | 2025-02-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| WO2025188830A1 (en) * | 2024-03-06 | 2025-09-12 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US952A (en) | 1838-09-27 | I antoni bengini | ||
| US10065A (en) | 1853-10-04 | Improvement in machines for topping cotton jn the field | ||
| FI3936130T3 (fi) * | 2014-05-06 | 2024-04-23 | Neurocrine Biosciences Inc | Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon |
| US20190015396A1 (en) * | 2015-06-23 | 2019-01-17 | Neurocrine Biosciences, Inc. | Vmat2 inhibitors for treating neurological diseases or disorders |
| KR20230170136A (ko) * | 2017-01-27 | 2023-12-18 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| WO2018164996A1 (en) * | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| SG11202100303QA (en) * | 2018-08-15 | 2021-02-25 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
-
2020
- 2020-05-08 EA EA202193012A patent/EA202193012A1/ru unknown
- 2020-05-08 SG SG11202111465RA patent/SG11202111465RA/en unknown
- 2020-05-08 AU AU2020270145A patent/AU2020270145A1/en not_active Abandoned
- 2020-05-08 MX MX2021013132A patent/MX2021013132A/es unknown
- 2020-05-08 PH PH1/2021/552745A patent/PH12021552745A1/en unknown
- 2020-05-08 TW TW109115397A patent/TWI850377B/zh active
- 2020-05-08 CN CN202080034710.XA patent/CN114340624A/zh active Pending
- 2020-05-08 IL IL321020A patent/IL321020A/en unknown
- 2020-05-08 BR BR112021020709A patent/BR112021020709A2/pt unknown
- 2020-05-08 EP EP20729429.9A patent/EP3965764A1/en active Pending
- 2020-05-08 CA CA3136466A patent/CA3136466A1/en active Pending
- 2020-05-08 WO PCT/US2020/032188 patent/WO2020227672A1/en not_active Ceased
- 2020-05-08 MA MA055893A patent/MA55893A/fr unknown
- 2020-05-08 KR KR1020217039903A patent/KR20220007105A/ko not_active Ceased
- 2020-05-08 JP JP2021565932A patent/JP2022531696A/ja active Pending
- 2020-08-31 US US17/007,710 patent/US20200397779A1/en not_active Abandoned
-
2021
- 2021-10-11 JO JOP/2021/0274A patent/JOP20210274A1/ar unknown
- 2021-10-21 US US17/506,883 patent/US20220040169A1/en not_active Abandoned
- 2021-11-08 IL IL287902A patent/IL287902A/en unknown
-
2024
- 2024-10-24 JP JP2024187589A patent/JP2025013963A/ja active Pending
-
2025
- 2025-10-22 AU AU2025256123A patent/AU2025256123A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3043785B1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| US10537566B2 (en) | Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis | |
| JP2020514318A5 (enExample) | ||
| JP2022544711A5 (enExample) | ||
| CN117137912A (zh) | 选择性s1p1受体激动剂的给药方案 | |
| JP6091593B2 (ja) | 慢性閉塞性肺疾患の急性増悪の治療におけるピラゾール誘導体の使用 | |
| JP2022145949A (ja) | 特定の患者集団において神経変性障害を処置する方法 | |
| JP2014517050A5 (enExample) | ||
| IL321020A (en) | Methods of administering certain vmat2 inhibitors | |
| Khurmi et al. | Randomized double-blind comparison of gallopamil and propranolol in stable angina pectoris | |
| JP2019535760A (ja) | フルピルチンを用いた発達障害および／または発作性障害の処置方法 | |
| JP2023520469A5 (enExample) | ||
| JP2021152060A (ja) | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 | |
| WO2021176070A1 (en) | Methods of slowing brain volume loss | |
| US20230398105A1 (en) | Treatment regimens for parkinson's disease | |
| IL272834B1 (en) | Compositions of amantadine, their preparation, and methods of use | |
| JP2018530612A5 (enExample) | ||
| US20240277662A1 (en) | Administration of a Compound to Individuals with Hepatic Impairment | |
| JP2021530568A5 (enExample) | ||
| US12357616B2 (en) | Methods of treating multiple sclerosis | |
| EP4251158A1 (en) | Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist | |
| McCoy et al. | Treatment of Tardive Dyskinesia with High Dose Vitamin B6 Associated with Depression | |
| AU2023358704A2 (en) | Methods of reducing physical dependence to neuropsychiatric treatments | |
| JP2024541770A5 (enExample) | ||
| CN116761604A (zh) | 用α-7烟碱型乙酰胆碱受体激动剂治疗当众讲话焦虑 |